Discovery and Development of Antiretroviral Agents – HIV

InPheno has been assembling a precious collection of essential tools to meet the complexity of discovery and development of antiretroviral agents. Antiretroviral drugs can suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering when use is made of a potent antiretroviral treatment, particularly in early stages of the disease. InPheno’s HIV platform is well suited for the identification and detailed study of novel antiretroviral drug candidates targeting any key viral function.

Our comprehensive HIV platform allows for the evaluation of antiviral activities in established cell lines and / or in human primary cells using either recombinant viruses or well characterized clinical isolates. All our HIV assays recapitulate the entire virus life cycle and are replicative, be they performed using primary cells or established cell lines.

Our platform enables:
• High throughput screening for new antiviral principles, be they synthetic compounds or natural products
• Activity Profiling of lead candidate inhibitors
• Identification of the mode of action of lead compounds
• Drug combination studies
• In vitro selection of resistant viruses and their characterization
• Functional characterization of neutralizing antibodies for vaccine studies
• Phenotypic resistance testing starting from primary clinical specimens

Available assets for your studies include:
• Extended bank of characterized, fully infectious recombinant HIV-1 isolates and variants
• Clonal HIV-1 variants with individual or complex mutations in protease, reverse transcriptase, integrase, or env genes
• Characterized (multi-)drug resistant HIV-1 mutants
• Service for engineering HIV-1 variants according to your needs
• HIV-1 clinical isolates of all common subtypes
• HIV-2 clinical isolates

For more information or to discuss the discovery and development of antiretroviral agents – HIV please contact us directly.